Ionis Pharmaceuticals, Inc.(IONS) Stock Research - Grey Stern Research

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis

$32.91 (0.55%)

IONS Financial Performance


Use the table below to view Ionis Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $32.73 -
52 Week Low $30.23 -
52 Week High $52.34 -
Market Cap $5.2 Billion 11/18
Gross Margin 98% 3/18
Profit Margin -46% 15/18
EBITDA margin -36% 12/18
Q4 - 2024 Revenue $226.6 Million 8/18
Q4 - 2024 Earnings -$104.3 Million 16/18
Q4 - 2024 Free Cash Flow -$144.2 Million 16/18
Trailing 4 Quarters Revenue $646.8 Million 10/18
Trailing 4 Quarters Earnings -$453.6 Million 15/18
Quarterly Earnings Growth -1027% 18/18
Annual Earnings Growth -1% 10/18
Quarterly Revenue Growth -30% 15/18
Annual Revenue Growth -15% 15/18
Cash On Hand $242.1 Million 10/18
Short Term Debt $9.3 Million 5/18
Long Term Debt $1.4 Billion 3/18

Ionis Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Ionis Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 7/18
PS 8.04 7/18
PB 8.84 9/18
PC 21.49 9/18
Liabilities to Equity 4.11 6/18
ROA -0.15 9/18
ROE -0.77 13/18
Current Ratio 1.24 12/18
Quick Ratio 0.95 10/18
Long Term Debt to Equity 2.39 4/18
Debt to Equity 2.41 4/18
Burn Rate 1.49 8/18
Cash to Cap 0.05 10/18
CCR 1.38 4/18
EV to EBITDA -79.22 11/18
EV to Revenue 9.86 7/18

Company Details

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

CEO: Dr. Stanley Crooke

Website: https://www.ionispharma.com

Address: 2855 Gazelle Ct Carlsbad, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Ionis Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Ionis Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $36.9 Billion
BioMarin Pharmaceutical Inc. BMRN $13.6 Billion
Exelixis, Inc. EXEL $10.3 Billion
Halozyme Therapeutics, Inc. HALO $8.0 Billion
Viking Therapeutics, Inc. VKTX $3.2 Billion
Incyte Corporation INCY $12.0 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Sarepta Therapeutics, Inc. SRPT $7.2 Billion
Seagen Inc. SGEN $43.2 Billion
Arrowhead Pharmaceuticals, Inc. ARWR $2.0 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Iovance Biotherapeutics, Inc. IOVA $1.2 Billion
Madrigal Pharmaceuticals, Inc. MDGL $7.5 Billion
PTC Therapeutics, Inc. PTCT $4.5 Billion
Apellis Pharmaceuticals, Inc. APLS $3.0 Billion
Krystal Biotech, Inc. KRYS $5.4 Billion
Terns Pharmaceuticals, Inc. TERN $284.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
IONS Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 226.6 Million -$104.3 Million
Q3 2024 $ 75.7 Million -$140.5 Million
Q2 2024 $ 225.0 Million -$66.0 Million
Q1 2024 $ 119.5 Million -$142.8 Million
Q4 2023 $ 324.5 Million -$9.3 Million
Q3 2023 $ 144.0 Million -$147.0 Million
Q2 2023 $ 188.4 Million -$85.3 Million
Q1 2023 $ 131.0 Million -$124.0 Million

View All

IONS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $242.1 Million $3.0 Billion $1.4 Billion $588.4 Million
Q3 2024 $334.6 Million $3.1 Billion $1.4 Billion $662.5 Million
Q2 2024 $2.1 Billion $2.7 Billion $251.0 Million $264.0 Million
Q1 2024 $348.9 Million $2.8 Billion $2.0 Billion $296.5 Million
Q4 2023 $399.3 Million $3.0 Billion $1.5 Billion $386.7 Million
Q3 2023 $352.1 Million $2.9 Billion $1.4 Billion $315.0 Million
Q2 2023 $424.8 Million $3.0 Billion $1.5 Billion $428.3 Million
Q1 2023 $309.0 Million $2.9 Billion $1.4 Billion $487.0 Million

View All

IONS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$144.2 Million -$28.0 Million -$92.5 Million
Q3 2024 -$108.8 Million $6.2 Million $40.6 Million
Q2 2024 $0 $0 $0
Q1 2024 -$155.7 Million -$5.7 Million -$50.4 Million
Q4 2023 $33.7 Million $819,000 $47.2 Million
Q3 2023 $1,600 $0 $1,600
Q2 2023 $1,400 $0 $1,400
Q1 2023 -$145.7 Million -$11.7 Million $32.6 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions